GSK2190915A - Bioavailability Study

Summary

GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor that reduces inflammation in cells. This study will evaluate three capsule and two tablet formulations to select the optimal formulation for further development. Safety will be assessed through clinical laboratory testing, 12-lead electrocardiogram (ECG), vital signs and Adverse Event/ Serious Adverse Event (AE/ SAE) recording.

Timeline

Start

2009-04-20

Primary completion

2010-06-08

Completion

2010-06-08

Drugs

Indications